Related Experiment Video
Updated: Jun 11, 2025

08:00
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
Published on: April 16, 2019
18.0K
Overcoming Challenges: Haemostasis in a Clival Plasmacytoma
Akshat Kushwaha1, Lokesh Kumar Penubarthi1, Ngohlaki Khaimeichho1
1Department of Otorhinolaryngology, JIPMER, Puducherry, India.
Summary
Solitary clival plasmacytomas are rare tumors. This case report details managing this challenging, vascular tumor using endoscopic skull base surgery (ESBS), highlighting surgical difficulties.
Area of Science:
- Neurosurgery
- Oncology
- Pathology
Background:
- Solitary plasmacytomas of the clivus are exceptionally rare, with fewer than 20 reported cases.
- Current diagnostic and management strategies lack a definitive gold standard.
- Endoscopic skull base surgery (ESBS) offers reduced morbidity but presents significant surgical challenges due to the clivus's critical location and potential for intraoperative bleeding.
Purpose of the Study:
- To present a case report on the management of a rare solitary clival plasmacytoma.
- To discuss the challenges encountered during surgical intervention for this vascular tumor.
- To contribute to the limited literature on clival plasmacytomas and their surgical treatment.
Main Methods:
- A case report detailing the diagnosis and surgical management of a solitary clival plasmacytoma.
- Utilization of endoscopic skull base surgery (ESBS) for tumor resection.
- Discussion of intraoperative challenges, particularly bleeding control in a vascular tumor.
Main Results:
- Successful resection of a solitary clival plasmacytoma was achieved.
- Significant intraoperative bleeding was encountered due to the tumor's vascularity.
- The case highlights the technical difficulties associated with ESBS in this anatomical region.
Conclusions:
- Management of solitary clival plasmacytomas remains challenging due to rarity and tumor characteristics.
- ESBS is a viable, less morbid approach but requires meticulous surgical technique for vascular tumors.
- Further case reports are crucial for refining diagnostic and therapeutic strategies for clival plasmacytomas.
Related Concept Videos
Formation of the Platelet Plug
5.1K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
5.1K
Introduction to Hemostasis
6.4K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
6.4K
Venous Thrombosis III: Interprofessional Care
3
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
3
Clot Retraction and Fibrinolysis
4.7K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
4.7K
Disorders of Hemostasis
738
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
738
Extrinsic and Intrinsic Pathways of Hemostasis
6.3K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
6.3K

